BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing.

BioCryst Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Therapeutics, Clinical Trials sector. The company focuses on Biotechnology and has secured $379.2B in funding across 216 round(s). With a team of 501-1000 employees, BioCryst Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - BioCryst Pharmaceuticals, raised $1.9M. Discover more about their projects, partnerships, and impact on our platform.